Pfizer PFE Biopharma — Provision
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
Item 1.
FAQ
- What is Pfizer's biopharma — provision?
- Pfizer (PFE) reported biopharma — provision of $47M in Q1 2026.
- How has Pfizer's biopharma — provision changed year-over-year?
- Pfizer's biopharma — provision decreased by 92.4% year-over-year, from $617M to $47M.
- What is the long-term trend for Pfizer's biopharma — provision?
- Over 3 years (2022 to 2025), Pfizer's biopharma — provision has grown at a 49.9% compound annual growth rate (CAGR), from $796M to $2.68B.
- What does biopharma — provision mean?
- Refers to the estimated amount set aside for specific liabilities or tax obligations related to the biopharmaceutical segment's operations. This reflects management's assessment of potential future outflows that are probable and estimable.
Ask your AI about Pfizer's biopharma — provision.
Connect your AI assistant and compare it to peers, right in your chat.
